-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and...
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
Seeking Alpha / 7 hours ago 4 Views
Comments